Search Result

Results for "

anti-tuberculosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (13) Bacterial (55) DNA/RNA Synthesis (1) Fungal (3) Potassium Channel (1) Reactive Oxygen Species (1) STAT (3) Topoisomerase (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Infection (55) Inflammation/Immunology (9)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146057

Antituberculosis agent-2	Bacterial	Infection
Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against agent-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 μg/mL against M. tuberculosis H₃₇R_v, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability .

HY-151205

Antituberculosis agent-3	Bacterial	Infection Inflammation/Immunology
Antituberculosis agent-3 (Compound 2) is an antituberculosis agent. Antituberculosis agent-3 shows anti-mycobacterial activity, and can inhibit M. tuberculosis H37Rv strain growth (MIC=12.5 μg/mL) .

HY-152136

Antituberculosis agent-6	Bacterial Fungal	Infection
Antituberculosis agent-6 (compound 9g) is a potent antimycobacterial agent. Antituberculosis agent-6 shows significant activity against M. tuberculosis, with a MIC of 3.49 μM. Antituberculosis agent-6 also shows good antifungal activity against A. niger, with a MIC of 62.50 μM. Antituberculosis agent-6 shows high GI absorption .

HY-146055

Antituberculosis agent-1

Bacterial Infection

Antituberculosis agent-1 (Compound 8a) is an antituberculosis agent with an MIC of 3.84 µg/mL against M. tuberculosis H₃₇R_v .

Antituberculosis agent-1	Bacterial	Infection
Antituberculosis agent-1 (Compound 8a) is an antituberculosis agent with an MIC of 3.84 µg/mL against M. tuberculosis H₃₇R_v .

HY-152137

Antituberculosis agent-7	Bacterial Fungal Antibiotic	Infection Inflammation/Immunology
Antituberculosis agent-7, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis with a MIC of 31.25 μM. Antituberculosis agent-7 shows good antifungal activity against A. niger with a MIC of 62.5 μM. Antituberculosis agent-7 shows excellent antimycobacterial activity with MIC 3.41 μM for M. tuberculosis H37Rv .

HY-151514

Antituberculosis agent-5	Bacterial	Infection
Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC₅₀ value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .

HY-152138

Antituberculosis agent-8	Bacterial Fungal	Infection
Antituberculosis agent-8 (Compound 9i) is an antitubercular agent with an MIC of 3.53 μM (1.6 μg/mL) against **M. tuberculosis* H37Rv**. Antituberculosis* agent-8 also shows good antifungal activity against A. niger with an MIC of 62.50 μM .

HY-149064

Antituberculosis agent-9

Bacterial Infection

Antituberculosis agent-9 (Compound 5a) is an orally active antitubercular agent with an MIC of 0.5 μg/mL against H37Ra .
HY-W716673

Ftivazide

Phthivazide
Bacterial Infection

Ftivazide has anti-tuberculosis activity .

Antituberculosis agent-9	Bacterial	Infection
Antituberculosis agent-9 (Compound 5a) is an orally active antitubercular agent with an MIC of 0.5 μg/mL against H37Ra .

Ftivazide Phthivazide	Bacterial	Infection
Ftivazide has anti-tuberculosis activity .

HY-W039897

Methyl α-D-mannopyranoside 1 Publications Verification α-Methyl-D-mannoside	Bacterial	Inflammation/Immunology
Methyl α-D-mannopyranoside could target macrophages in anti-tuberculosis inhalation therapy .

HY-146348

Tuberculosis inhibitor 5	Bacterial	Infection
Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent .

HY-142031

4-Piperidinecarboxamide	Bacterial	Infection
4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .

HY-148478

MMV688845 (R)-GSK1729177A	DNA/RNA Synthesis	Infection
MMV688845 is a nontuberculous mycobacteria (NTM) RNA polymerase inhibitor with bactericidal activity against Mycobacterium abscessus and anti-tuberculosis efficacy .

HY-126597

Chaetoglobosin C	Bacterial	Infection
Chaetoglobosin C (Compound 4) is a anthraquinone-chromone compound derived from the fungus Chaetomium globosum KMITL-N0802. Chaetoglobosin C has anti-tuberculosis activity .

HY-N0872

Isosteviol (-)-Isosteviol; iso-Steviol	Reactive Oxygen Species Topoisomerase	Cardiovascular Disease Cancer
Isosteviol ((-)-Isosteviol) is a derivative of Stevioside through acid catalyzed hydrolysis of Stevioside. Isosteviol inhibits DNA polymerase and DNA topoisomerase and has antibacterial, anticancer and anti-tuberculosis effects .

HY-151956

Mtb-cyt-bd oxidase-IN-7	Bacterial	Infection
Mtb-cyt-bd oxidase-IN-7 is a cytochrome bd terminal oxidase (Cyt-bd) inhibitor with a K_d value of 4.17 μM. Mtb-cyt-bd oxidase-IN-7 shows anti-tuberculosis activities .

HY-139695

Spectinamide 1599

Bacterial Infection

Spectinamide-1599 is a combination partner for anti-tuberculosis research.
HY-14990

Sudoterb

LL 3858
Bacterial Infection

Sudoterb (LL 3858) is an orally active anti-Tuberculosis agent .
HY-14990A

Sudoterb hydrochloride

LL 3858 hydrochloride
Bacterial Infection

Sudoterb (LL 3858) hydrochloride is an orally active anti-Tuberculosis agent .

Spectinamide 1599	Bacterial	Infection
Spectinamide-1599 is a combination partner for anti-tuberculosis research.

Sudoterb LL 3858	Bacterial	Infection
Sudoterb (LL 3858) is an orally active anti-Tuberculosis agent .

Sudoterb hydrochloride LL 3858 hydrochloride	Bacterial	Infection
Sudoterb (LL 3858) hydrochloride is an orally active anti-Tuberculosis agent .

HY-150967

MmpL3-IN-1	Bacterial	Infection
MmpL3-IN-1 (compound 32) is a potent Mycobacterial membrane protein large 3 (MmpL3) inhibitor. MmpL3-IN-1 has anti-tuberculosis activity with the MIC<0.016 μg/mL in M. tuberculosis and can be used in studies of drug-resistant tuberculosis .

HY-112091

GSK2200150A

Bacterial Infection

GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.

GSK2200150A	Bacterial	Infection
GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.

HY-76210

5-Hydroxypyrazine-2-Carboxylic Acid 1 Publications Verification	Bacterial Antibiotic	Others
5-Hydroxypyrazine-2-Carboxylic Acid, a metabolite of anti-tuberculosis drug pyrazinamide (PZA).

HY-153009

MMV676584

Bacterial Infection

MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel agent candidate for eumycetoma .

MMV676584	Bacterial	Infection
MMV676584 has anti-tuberculosis avtivity. MMV676584 is a novel agent candidate for eumycetoma .

HY-145286

IMPDH2-IN-2	Bacterial	Infection Cancer
IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a K_i,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent .

HY-12485

TBA-354

Bacterial Antibiotic Infection

TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains.

TBA-354	Bacterial Antibiotic	Infection
TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains.

HY-146158

WX-081	Bacterial Potassium Channel Antibiotic	Infection
WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.

HY-126131

anti-TB agent 1

Bacterial Infection

anti-TB agent 1 is a potent and orally active anti-tuberculosis agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH .

anti-TB agent 1	Bacterial	Infection
anti-TB agent 1 is a potent and orally active *anti-tuberculosis* agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH .

HY-128866

TBAJ-876	Bacterial	Infection
TBAJ-876 is the inhibitor of mycobacterium tuberculosis. TBAJ-876 is the analogue of the anti-tuberculosis agent Bedaquiline. TBAJ-876 has the potential for the research of tuberculosis .

HY-W028047

JFD01307SC	Bacterial	Infection Inflammation/Immunology
JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis .

HY-148564

TBI-166	Bacterial	Infection
TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) .

HY-162028

GaMF1.39	Bacterial	Infection
GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors .

HY-162094

Antitubercular agent-44

Bacterial Infection

Antitubercular agent-44 (compound 21b) has anti-tuberculosis (H37Rv MIC = 0.06 μM). Antitubercular agent-44 has oral activity .

Antitubercular agent-44	Bacterial	Infection
Antitubercular agent-44 (compound 21b) has anti-tuberculosis (H37Rv MIC = 0.06 μM). Antitubercular agent-44 has oral activity .

HY-N8388

Collinin	Bacterial	Infection
Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .

HY-W018677S

Quinoxaline-d4	Antibiotic	Infection
Quinoxaline-d₄ is the deuterium labeled Quinoxaline[1]. Quinoxaline is a chemical compound that acts as an intermediate for anti-tuberculosis agent Pyrazinamide. Quinoxaline presents a structure that is similar to quinolone antibiotics[2].

HY-163107

Antimycobacterial agent-7	Bacterial	Infection
Antimycobacterial agent-7 (compound 4) is a 1,2,4-triazole anti-tuberculosis agent (MIC: 2 μg/mL). Antimycobacterial agent-7 inhibits Mtb KatG and causes the accumulation of ROS in Mtb cells. ROS produces oxidative damage, leading to the death of Mtb .

HY-117145

Thiophene-2	Bacterial	Infection
Thiophene-2 (TP2) is a specific polyketide synthase 13 (Pks13) inhibitor. Thiophene-2 inhibits mycolic acid biosynthesis and rapidly leads to mycobacterial cell death. Thiophene-2 is active against Mycobacterium tuberculosis with a MIC value of 1 μM, and has potent anti-tuberculosis activity .

HY-111747

TBAJ-587	Bacterial	Infection Cardiovascular Disease
TBAJ-587, a potent *anti-tuberculosis* agent, inhibits M.tb strain H37Rv growth with MIC₉₀s of 0.006 and <0.02 µg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .

HY-122643

NITD-916	Bacterial	Infection
NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active and highly lipophilic mycobacterial enoyl reductase InhA inhibitor with an IC₅₀ of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 has potent anti-tuberculosis effects .

HY-151598

Pks13-TE inhibitor 2	Bacterial	Infection
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-151599

Pks13-TE inhibitor 3	Bacterial	Infection
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-B1040

Ftaxilide

Bacterial Infection

Ftaxilide is a novel antituberculosis agent.

Ftaxilide	Bacterial	Infection
Ftaxilide is a novel antituberculosis agent.

HY-N1103

Vasicine Peganine	Bacterial	Inflammation/Immunology
Vasicine (peganine) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity .

HY-139863

Antibacterial agent 62	Bacterial	Infection
Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.

HY-100531

DprE1-IN-2

Bacterial Infection

DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC₅₀ of 28 nM. DprE1-IN-2 has antituberculosis effect .

DprE1-IN-2	Bacterial	Infection
DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC₅₀ of 28 nM. DprE1-IN-2 has antituberculosis effect .

HY-155067

Antitubercular agent-38	Bacterial	Infection
Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .

HY-156412

DHFR-IN-10	Bacterial	Infection
DHFR-IN-10 (compound 4c) is a potent DHFR inhibitor, with an IC₅₀ of 4.21 μM for M. tuberculosis DHFR enzyme. DHFR-IN-10 exhibits potent antituberculosis efficiency .

HY-134940

Quabodepistat OPC-167832	Bacterial	Infection Inflammation/Immunology
Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with an IC₅₀ of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis .

HY-12903

Macozinone 4 Publications Verification PBTZ169	Bacterial Antibiotic	Infection
Macozinone (PBTZ169) is a bactericidal benzothiazinone and a potent DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) inhibitor. Macozinone inhibits the essential flavoprotein DprE1 by forming a covalent bond with the active-site Cys387 residue. Macozinone has antituberculosis effect .

HY-155558

MptpB-IN-2	Antibiotic	Infection
MptpB-IN-2 (compound 20) is a selective *mycobacterium tuberculosis* protein tyrosine phosphatase B (MptpB) inhibitor with IC₅₀*s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis* activity with a MIC of 64.9 μM for Mtb H37Rv .

HY-146448

PXYD3	Bacterial	Infection
PXYD3 is a ribosomal protein S1 (RpsA) antagonist with K_ds of 5.66 and 6.91 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb) .

Cat. No.	Product Name

HY-L142

Anti-tuberculosis Compound Library

96 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 96 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks